

Adeera Levin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10794975/publications.pdf>

Version: 2024-02-01

269
papers

37,658
citations

18436

62
h-index

3021

188
g-index

279
all docs

279
docs citations

279
times ranked

34341
citing authors

#	ARTICLE	IF	CITATIONS
1	The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2023, 43, 139-144.	1.1	7
2	Creating a provincial post COVID-19 interdisciplinary clinical care network as a learning health system during the pandemic: Integrating clinical care and research. <i>Learning Health Systems</i> , 2023, 7, .	1.1	6
3	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 244-256.e1.	2.1	23
4	Global Estimates of Capacity for Kidney Transplantation in World Countries and Regions. <i>Transplantation</i> , 2022, 106, 1113-1122.	0.5	26
5	Assessing Global Kidney Nutrition Care. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 38-52.	2.2	23
6	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	2.2	9
7	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5
8	Emerging Role of Clinical Genetics in CKD. <i>Kidney Medicine</i> , 2022, 4, 100435.	1.0	12
9	Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 985-995.	3.0	45
10	Adverse changes in key chronic kidney disease care outcome metrics since the onset of the COVID-19 pandemic: experience from an established provincial renal program. <i>Kidney International</i> , 2022, , .	2.6	0
11	Nutritional Status, Nutritional Phenotypes, and Oral Nutritional Supplement Prescription Patterns Among Patients With Non-Dialysis Chronic Kidney Disease in British Columbia. , 2022, 32, 414-422.		3
12	Global eHealth capacity: secondary analysis of WHO data on eHealth and implications for kidney care delivery in low-resource settings. <i>BMJ Open</i> , 2022, 12, e055658.	0.8	3
13	Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210803.	0.6	5
14	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. <i>Diabetes Care</i> , 2022, 45, 1445-1452.	4.3	18
15	FC 122: Effects of Canagliflozin on Cardiovascular and Kidney Events in Patients With Chronic Kidney Disease With and Without Peripheral Vascular Disease: Integrated Analysis From the Canvas Program and Credence Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
16	Protocol for a Multistage Mixed-Methods Evaluation of Multidisciplinary Chronic Kidney Disease Care Quality Following Integration of Virtual and In-Person Care During the COVID-19 Pandemic. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812211031.	0.6	1
17	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	1.0	3
18	Sex, Gender, and Cardiovascular Disease in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2022, 42, 197-207.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Anticoagulation for Patients With Atrial Fibrillation and End-Stage Renal Disease on Dialysis: A National Survey. <i>Canadian Journal of Cardiology</i> , 2021, 37, 924-928.	0.8	6
20	Insights from CREDESCENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	2.6	93
21	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021, 99, 551-554.	2.6	2
22	Advancing Palliative Care in Patients With CKD: From Ideas to Practice. <i>American Journal of Kidney Diseases</i> , 2021, 77, 420-426.	2.1	11
23	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 79-87.	2.2	18
24	Adapting Nephrology Training Curriculum in the Era of COVID-19. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812098844.	0.6	2
25	Maintaining the Uptake of Peritoneal Dialysis During the COVID-19 Pandemic: A Research Letter. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812098626.	0.6	8
26	Balancing the Needs of Acute and Maintenance Dialysis Patients during the COVID-19 Pandemic. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1122-1130.	2.2	9
27	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	2.2	37
28	QALYs, DALYs and Now PALYs: Strengthening the Argument for Prevention of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 771-773.	3.0	1
29	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 315-325.	2.1	62
30	Hemodialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 326-335.e1.	2.1	24
31	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDESCENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
32	Slowing Progression in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1117-1119.	2.2	9
33	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <i>Kidney International Reports</i> , 2021, 6, 1130-1140.	0.4	1
34	Therapy for Anemia in Chronic Kidney Disease – New Interventions and New Questions. <i>New England Journal of Medicine</i> , 2021, 384, 1657-1658.	13.9	3
35	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
36	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America. <i>Kidney International Supplements</i> , 2021, 11, e35-e46.	4.6	10

#	ARTICLE	IF	CITATIONS
37	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in South Asia. <i>Kidney International Supplements</i> , 2021, 11, e97-e105.	4.6	10
38	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Eastern and Central Europe. <i>Kidney International Supplements</i> , 2021, 11, e24-e34.	4.6	5
39	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa. <i>Kidney International Supplements</i> , 2021, 11, e11-e23.	4.6	15
40	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East. <i>Kidney International Supplements</i> , 2021, 11, e47-e56.	4.6	8
41	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Oceania and South East Asia. <i>Kidney International Supplements</i> , 2021, 11, e86-e96.	4.6	5
42	International Society of Nephrology Global Kidney Health Atlas: structures, organization and services for the management of kidney failure in North and East Asia. <i>Kidney International Supplements</i> , 2021, 11, e77-e85.	4.6	10
43	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	1.0	60
44	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Newly Independent States and Russia. <i>Kidney International Supplements</i> , 2021, 11, e57-e65.	4.6	3
45	Global variation in kidney care: national and regional differences in the care and management of patients with kidney failure. <i>Kidney International Supplements</i> , 2021, 11, e1-e3.	4.6	3
46	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean. <i>Kidney International Supplements</i> , 2021, 11, e66-e76.	4.6	3
47	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. <i>Kidney International Supplements</i> , 2021, 11, e106-e118.	4.6	29
48	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021, 99, 1280-1295.	2.6	103
49	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021, 11, e047245.	0.8	25
50	Risk of tuberculosis associated with chronic kidney disease: a population-based analysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 197-198.	0.4	3
51	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. <i>CJC Open</i> , 2021, 3, 965-975.	0.7	15
52	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. <i>Kidney International Reports</i> , 2021, 6, 1775-1787.	0.4	100
53	The state of the global nephrology workforce: a joint ASN-ERA-EDTA-ISN investigation. <i>Kidney International</i> , 2021, 100, 995-1000.	2.6	18
54	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80

#	ARTICLE	IF	CITATIONS
55	Validity of different dose reduction criteria for apixaban. <i>American Heart Journal</i> , 2021, 238, 12-15.	1.2	2
56	Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2021, 100, 516-526.	2.6	156
57	Standardised Outcomes in Nephrology – Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. <i>Trials</i> , 2021, 22, 612.	0.7	12
58	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 159-167.	0.4	9
59	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	1.4	15
60	Assessment of an Interactive Digital Health-Based Self-management Program to Reduce Hospitalizations Among Patients With Multiple Chronic Diseases. <i>JAMA Network Open</i> , 2021, 4, e2140591.	2.8	10
61	Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e053857.	0.8	3
62	Predicting kidney failure risk after acute kidney injury among people receiving nephrology clinic care. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 836-845.	0.4	11
63	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. <i>American Journal of Kidney Diseases</i> , 2020, 75, 84-104.	2.1	311
64	Epidemiology of Chronic Kidney Disease – Scope of the Problem. , 2020, , 75-89.		3
65	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
66	High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients. <i>Clinica Chimica Acta</i> , 2020, 501, 234-240.	0.5	11
67	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 903-914.	5.5	73
68	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.	3.0	82
69	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
70	International perspectives on patient involvement in clinical trials in nephrology. <i>Kidney International</i> , 2020, 98, 566-571.	2.6	12
71	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m ² . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
72	Sixty (plus one) breakthrough discoveries in nephrology. <i>Kidney International</i> , 2020, 98, 1362-1366.	2.6	3

#	ARTICLE	IF	CITATIONS
73	Alport Syndrome Classification and Management. <i>Kidney Medicine</i> , 2020, 2, 639-649.	1.0	45
74	A Provincial Survey of the Contemporary Management of Autosomal Dominant Polycystic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812094829.	0.6	2
75	The CSN COVID-19 Rapid Response Program. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812094911.	0.6	1
76	Performance of StatSensor Point-of-Care Device for Measuring Creatinine in Patients With Chronic Kidney Disease and Postkidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812097071.	0.6	5
77	Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096895.	0.6	4
78	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CRENDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
79	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
80	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020, 97, 1117-1129.	2.6	407
81	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1761-1769.	0.4	5
82	The role of kidney transplantation as a component of integrated care for chronic kidney disease. <i>Kidney International Supplements</i> , 2020, 10, e78-e85.	4.6	13
83	Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis. <i>Kidney International Supplements</i> , 2020, 10, e55-e62.	4.6	24
84	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1433-1444.	2.2	40
85	Availability and Affordability of Kidney Health Laboratory Tests around the Globe. <i>American Journal of Nephrology</i> , 2020, 51, 959-965.	1.4	7
86	The Global Kidney Health Atlas: Burden and Opportunities to Improve Kidney Health Worldwide. <i>Annals of Nutrition and Metabolism</i> , 2020, 76, 25-30.	1.0	5
87	Renal pathology practice globally: identifying needs and meeting the challenge. <i>Kidney International</i> , 2019, 96, 258-261.	2.6	5
88	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
89	Glomerular Filtration Rate-Specific Cutoffs Can Refine the Prognostic Value of Circulating Cardiac Biomarkers in Advanced Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1106-1113.	0.8	6
90	GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 50, 105-114.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Multidisciplinary Chronic Kidney Disease Clinic Practices: A Scoping Review. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811988266.	0.6	30
92	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, l5873.	2.4	131
93	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology, the, 2019, 7, 845-854.	5.5	595
94	Capacity of Kidney Care in Canada: Identifying Barriers and Opportunities. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811987054.	0.6	3
95	Prospective Biopsy-Based Study of CKD of Unknown Etiology in Sri Lanka. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 224-232.	2.2	27
96	CKD Hotspots: Challenges and Areas of Opportunity. Seminars in Nephrology, 2019, 39, 308-314.	0.6	26
97	Introduction: CKD Hotspots. Seminars in Nephrology, 2019, 39, 227-229.	0.6	1
98	CT of Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: Accuracy, Reproducibility, and Radiation Dose. Radiology, 2019, 291, 660-667.	3.6	10
99	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
100	The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care. , 2019, , 121-135.e6.		1
101	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	2.1	49
102	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. American Journal of Kidney Diseases, 2019, 73, 39-50.	2.1	11
103	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.4	6
104	What We Do and Do Not Know about Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Womenâ€™s Day. American Journal of Nephrology, 2018, 47, 103-114.	1.4	4
105	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: reflection on World Kidney Day and International Womenâ€™s Day. Journal of Nephrology, 2018, 31, 173-184.	0.9	7
106	What we do and do not know about women and kidney diseases: Questions unanswered and answers unquestioned. Pediatric Nephrology, 2018, 33, 529-540.	0.9	1
107	A Peculiar Case of Paraproteinemia and Elevated Creatinine. American Journal of Kidney Diseases, 2018, 71, A14-A15.	2.1	6
108	What We Do and Do Not Know About Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Womanâ€™s Day. American Journal of Hypertension, 2018, 31, 375-384.	1.0	0

#	ARTICLE	IF	CITATIONS
109	What We Do and Do Not Know about Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Woman's Day. Blood Purification, 2018, 45, 364-375.	0.9	5
110	Global challenges in kidney diseases. Nephrology Dialysis Transplantation, 2018, 33, 371-372.	0.4	5
111	Risk Factors for Prognosis in Patients With Severely Decreased GFR. Kidney International Reports, 2018, 3, 625-637.	0.4	35
112	Women and kidney disease: reflections on World Kidney Day 2018. Nephrologie Et Therapeutique, 2018, 14, 67-70.	0.2	2
113	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. Nefrologia, 2018, 38, 114-124.	0.2	0
114	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2018, 93, 1281-1292.	2.6	69
115	What We Do and Do Not Know about Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Women's Day. Nephron, 2018, 138, 249-260.	0.9	6
116	Building blocks toward sustainable kidney care around the world: results from a multinational survey by the International Society of Nephrology. Kidney International Supplements, 2018, 8, 27-29.	4.6	3
117	Global nephrology workforce: gaps and opportunities toward a sustainable kidney care system. Kidney International Supplements, 2018, 8, 52-63.	4.6	123
118	Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. Kidney International Supplements, 2018, 8, 64-73.	4.6	82
119	Global coverage of health information systems for kidney disease: availability, challenges, and opportunities for development. Kidney International Supplements, 2018, 8, 74-81.	4.6	24
120	Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. Kidney International Supplements, 2018, 8, 82-89.	4.6	13
121	Guidelines, policies, and barriers to kidney care: findings from a global survey. Kidney International Supplements, 2018, 8, 30-40.	4.6	21
122	Global overview of health systems oversight and financing for kidney care. Kidney International Supplements, 2018, 8, 41-51.	4.6	41
123	Women and kidney disease: reflections on World Kidney Day 2018. CKJ: Clinical Kidney Journal, 2018, 11, 7-11.	1.4	13
124	Women and Kidney Disease. Journal of Hypertension, 2018, 36, 705-708.	0.3	1
125	Women and kidney disease: reflections on World Kidney Day 2018. Nephrology Dialysis Transplantation, 2018, 33, 189-193.	0.4	13
126	Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 429-435.	2.2	11

#	ARTICLE	IF	CITATIONS
127	Women and kidney disease: reflections on World Kidney Day 2018. <i>Kidney International</i> , 2018, 93, 278-283.	2.6	38
128	What we know and do not know about women and kidney diseases: questions unanswered and answers unquestioned: reflection on World Kidney Day and International Women's Day. <i>Internal Medicine Journal</i> , 2018, 48, 113-123.	0.5	0
129	Women and kidney disease: Reflections on world kidney day 2018. <i>Journal of Renal Care</i> , 2018, 44, 3-11.	0.6	6
130	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Nefrologia</i> , 2018, 38, 114-124.	0.2	2
131	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: reflection on World Kidney Day and International Woman's Day. <i>BMC Nephrology</i> , 2018, 19, 66.	0.8	27
132	What We Do and Do Not Know about Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Women's Day. <i>Kidney Diseases (Basel)</i> , Tj ETQq0 0.2 rgBT /@verlock 10	0.2	0
133	What We Do and Do Not Know About Women and Kidney Diseases; Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811876165.	0.6	3
134	Women and Kidney Diseases: Questions Unanswered and Answers Unquestioned. <i>Kidney International Reports</i> , 2018, 3, 225-235.	0.4	6
135	External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for end-stage kidney disease. <i>Palliative Medicine</i> , 2018, 32, 395-403.	1.3	15
136	Long-term patient and kidney survival after coronary artery bypass grafting, percutaneous coronary intervention, or medical therapy for patients with chronic kidney disease. <i>Coronary Artery Disease</i> , 2018, 29, 8-16.	0.3	10
137	Contrast-associated acute kidney injury is a myth: We are not sure. <i>Intensive Care Medicine</i> , 2018, 44, 110-114.	3.9	19
138	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
139	What we do and do not know about women and kidney diseases " questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Nephrology</i> , 2018, 23, 199-209.	0.7	9
140	What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. <i>Nephrology @ Point of Care</i> , 2018, 4, 205930071775305.	0.2	0
141	FO068KIDNEY FAILURE AFTER AKI AMONG PEOPLE UNDER NEPHROLOGY CLINIC CARE: A PROVINCEWIDE COHORT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i47-i48.	0.4	0
142	Pregnancy in Chronic Kidney Disease: Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Different CKD Stages and Phases. <i>Journal of Clinical Medicine</i> , 2018, 7, 415.	1.0	38
143	Acute Kidney Injury in Pregnancy: The Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Prevention and Care of Pregnancy-Related AKI, in the Year Dedicated to Women and Kidney Diseases. <i>Journal of Clinical Medicine</i> , 2018, 7, 318.	1.0	28
144	Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 24-29.	2.2	10

#	ARTICLE	IF	CITATIONS
145	Women and kidney diseases: reflection on World Kidney Day and International Woman's Day. Archivos Argentinos De Pediatría, 2018, 116, e273-e278.	0.3	1
146	Nephrology in the Oceania-South East Asia region: perspectives and challenges. Kidney International, 2018, 94, 465-470.	2.6	7
147	Variability in Non-Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae. Canadian Journal of Cardiology, 2018, 34, 1010-1018.	0.8	33
148	Cardiovascular Outcomes Reported in Hemodialysis Trials. Journal of the American College of Cardiology, 2018, 71, 2802-2810.	1.2	16
149	What we do and do not know about women and kidney diseases; Questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation. Saudi Arabia, 2018, 29, 261.	0.4	1
150	Women and Kidney Disease: Reflections on World Kidney Day 2018. Nephrology Nursing Journal, 2018, 45, 65-70.	0.1	0
151	What We Do and Do Not Know About Women and Kidney Diseases: Questions Unanswered and Answers Unquestioned: Reflection on World Kidney Day and International Woman's Day. Iranian Journal of Kidney Diseases, 2018, 12, 65-77.	0.1	0
152	The KRESCENT Program (2005-2015). Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	0.6	4
153	Assessment of Global Kidney Health Care Status. JAMA - Journal of the American Medical Association, 2017, 317, 1864.	3.8	282
154	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet, The, 2017, 390, 1888-1917.	6.3	662
155	Evaluation of A 12-Month Pilot of Long-Term and Temporary Assisted Peritoneal Dialysis. Peritoneal Dialysis International, 2017, 37, 307-313.	1.1	38
156	Global Kidney Health Atlas (GKHA): design and methods. Kidney International Supplements, 2017, 7, 145-153.	4.6	37
157	A Rebuttal to "The CKD Classification System in the Precision Medicine Era". Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1711-1713.	2.2	4
158	Chronic kidney disease. Nature Reviews Disease Primers, 2017, 3, 17088.	18.1	558
159	Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study. BMC Nephrology, 2017, 18, 95.	0.8	10
160	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	1.4	194
161	Daily Intake of Grape Powder Prevents the Progression of Kidney Disease in Obese Type 2 Diabetic ZSF1 Rats. Nutrients, 2017, 9, 345.	1.7	18
162	Perspectives on Optimizing Care of Patients in Multidisciplinary Chronic Kidney Disease Clinics. Canadian Journal of Kidney Health and Disease, 2016, 3, 122.	0.6	15

#	ARTICLE	IF	CITATIONS
163	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. <i>Kidney International</i> , 2016, 89, 1144-1152.	2.6	139
164	Tuberculosis and chronic kidney disease: an emerging global syndemic. <i>Kidney International</i> , 2016, 90, 34-40.	2.6	94
165	Recognizing IgG4-Related Tubulointerstitial Nephritis. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 126.	0.6	12
166	Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. <i>Kidney International</i> , 2016, 90, 897-904.	2.6	51
167	Cystatin C and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 946-948.	1.2	11
168	International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. <i>BMC Nephrology</i> , 2016, 17, 121.	0.8	44
169	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	2.1	57
170	Past Decline Versus Current eGFR and Subsequent ESRD Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2447-2455.	3.0	78
171	The Lancet Kidney Campaign: an opportunity for partnerships. <i>Lancet, The</i> , 2016, 387, 1038-1039.	6.3	2
172	Predicting Progression in CKD: Perspectives and Precautions. <i>American Journal of Kidney Diseases</i> , 2016, 67, 779-786.	2.1	24
173	The β -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.	2.1	36
174	Perceptions of Prognostic Risks in Chronic Kidney Disease: A National Survey. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 88.	0.6	15
175	A Fine Balance: Developing Clinical Practice Guidelines in Areas Where Evidence is Lacking. <i>Seminars in Dialysis</i> , 2015, 28, 654-656.	0.7	5
176	Integrating Guidelines, CKD, Multimorbidity, and Older Adults. <i>American Journal of Kidney Diseases</i> , 2015, 65, 494-501.	2.1	19
177	Time to Revisit the Problem of CIN? The Low Incidence of Acute Kidney Injury with and without Contrast in Hospitalized Patients: An Observational Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 73.	0.6	13
178	Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. <i>American Journal of Kidney Diseases</i> , 2015, 65, 15-25.	2.1	68
179	High-Performance Information Search Filters for CKD Content in PubMed, Ovid MEDLINE, and EMBASE. <i>American Journal of Kidney Diseases</i> , 2015, 65, 26-32.	2.1	13
180	Epidemiology of Chronic Kidney Disease. , 2015, , 57-68.		2

#	ARTICLE	IF	CITATIONS
181	Transplant commercialism and organ trafficking: The Declaration of Istanbul with special relevance to disadvantaged populations living with kidney disease. <i>Clinical Nephrology</i> , 2015, 83 (2015), 85-89.	0.4	3
182	Geographic and facility-level variation in the use of peritoneal dialysis in Canada: a cohort study. <i>CMAJ Open</i> , 2014, 2, E36-E44.	1.1	18
183	ISNâ€™s ACCTS: global initiatives to improve clinical research. <i>Nature Reviews Nephrology</i> , 2014, 10, 426-427.	4.1	2
184	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. <i>Kidney International</i> , 2014, 86, 819-827.	2.6	70
185	Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1037-1047.	0.4	46
186	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1825-1833.	3.0	142
187	Remembering the forgotten non-communicable diseases. <i>BMC Medicine</i> , 2014, 12, 200.	2.3	82
188	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
189	Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. <i>Kidney International</i> , 2014, 85, 49-61.	2.6	565
190	The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 538-545.	1.4	15
191	Chronic kidney disease and support provided by home care services: a systematic review. <i>BMC Nephrology</i> , 2014, 15, 118.	0.8	27
192	Fluid Balance, Change in Serum Creatinine and Urine Output as Markers of Acute Kidney Injury Post Cardiac Surgery: An Observational Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 19.	0.6	9
193	The Canadian Society of Nephrology Methods in Developing and Adapting Clinical Practice Guidelines: A Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 5.	0.6	4
194	CKD Stage at Nephrology Referral and Factors Influencing the Risks of ESRD and Death. <i>American Journal of Kidney Diseases</i> , 2014, 63, 928-936.	2.1	37
195	Kidney Disease Guideline Profusion and Confusion: Unintended Consequences of Different Perspectives and Definitions. <i>American Journal of Kidney Diseases</i> , 2014, 63, 749-752.	2.1	4
196	Interventions for promoting adherence to fluid intake and dietary salt restriction in people with end-stage kidney disease. <i>The Cochrane Library</i> , 2014, , .	1.5	2
197	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19
198	Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). <i>BMC Nephrology</i> , 2013, 14, 121.	0.8	58

#	ARTICLE	IF	CITATIONS
199	The British Columbia Nephrologists™ Access Study (BCNAS) – a prospective, health services interventional study to develop waiting time benchmarks and reduce wait times for out-patient nephrology consultations. <i>BMC Nephrology</i> , 2013, 14, 182.	0.8	11
200	Evolving importance of kidney disease: from subspecialty to global health burden. <i>Lancet</i> , The, 2013, 382, 158-169.	6.3	874
201	Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. <i>Kidney International</i> , 2013, 83, 1001-1009.	2.6	14
202	Summary of KDIGO guideline: behind the scenes, need for guidance, and a framework for moving forward. <i>Kidney International</i> , 2013, , .	2.6	5
203	Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. <i>BMJ</i> , The, 2013, 346, f324-f324.	3.0	317
204	Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2013, 158, 825.	2.0	2,404
205	Activity-Based Funding Model Provides Foundation for Province-wide Best Practices in Renal Care. <i>Healthcare Quarterly</i> , 2013, 16, 49-54.	0.7	9
206	Biomarkers in native and transplant kidneys. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 619-627.	1.0	11
207	Progression, prediction, populations and possibilities. <i>Nature Reviews Nephrology</i> , 2012, 8, 70-72.	4.1	3
208	Age and Association of Kidney Measures With Mortality and End-stage Renal Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2349.	3.8	493
209	Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iii104-iii110.	0.4	23
210	Ongoing gaps in CKD and CVD care: re-evaluating strategies for knowledge dissemination. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1282-1284.	0.4	6
211	Does an Association Exist Between Pseudoexfoliation Syndrome and Chronic Kidney Disease?. <i>Journal of Glaucoma</i> , 2012, 21, 562-566.	0.8	8
212	Acute Kidney Injury and CKD: Chicken or Egg?. <i>American Journal of Kidney Diseases</i> , 2012, 59, 485-491.	2.1	59
213	On Being Better Kidney Doctors: Understanding Trajectories, Probabilities, Predictability, and People. <i>American Journal of Kidney Diseases</i> , 2012, 59, 475-477.	2.1	10
214	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	6.3	2,087
215	Early detection of CKD: the benefits, limitations and effects on prognosis. <i>Nature Reviews Nephrology</i> , 2011, 7, 446-457.	4.1	68
216	A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1553.	3.8	927

#	ARTICLE	IF	CITATIONS
217	TREAT: Implications for Guideline Updates and Clinical Care. American Journal of Kidney Diseases, 2010, 55, 984-987.	2.1	2
218	Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. Journal of Oncology Pharmacy Practice, 2010, 16, 113-119.	0.5	20
219	Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrology Dialysis Transplantation, 2010, 25, 2203-2209.	0.4	84
220	The Role of the Chronic Kidney Disease Clinic. , 2010, , 75-86.		1
221	Guidelines in nephrology: a new era of stimulating best care and best science. Nephrology News & Issues, 2009, 23, 45-6.	0.1	0
222	Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred Cohort. American Journal of Kidney Diseases, 2008, 52, 661-671.	2.1	240
223	KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD. American Journal of Kidney Diseases, 2008, 52, 811-825.	2.1	43
224	Regional Implementation of Creatinine Measurement Standardization. Journal of the American Society of Nephrology: JASN, 2008, 19, 164-169.	3.0	36
225	Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease. Current Cardiology Reviews, 2007, 3, 105-109.	0.6	0
226	N-acetylcysteine reduces urinary albumin excretion following contrast administration: evidence of biological effect. Nephrology Dialysis Transplantation, 2007, 22, 2520-2524.	0.4	22
227	Epoetin trials: randomised controlled trials don't always mimic observational data. Nephrology Dialysis Transplantation, 2007, 22, 684-686.	0.4	8
228	Appraisal of Evidence and Control of Bias in the Kidney Disease Outcomes Quality Initiative Guideline Development Process. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 8-10.	2.2	12
229	The treatment of anemia in chronic kidney disease: understandings in 2006. Current Opinion in Nephrology and Hypertension, 2007, 16, 267-271.	1.0	17
230	Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure—This study was presented in abstract form at the American Society of Nephrology meetings in 2005.. American Journal of Cardiology, 2007, 99, 1137-1142.	0.7	43
231	Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: a case series. Clinical and Experimental Nephrology, 2007, 11, 209-213.	0.7	18
232	Anemia and the Heart in Chronic Kidney Disease. Seminars in Nephrology, 2006, 26, 290-295.	0.6	19
233	Analysis of cardiovascular disease and kidney outcomes in multidisciplinary chronic kidney disease clinics: complex disease requires complex care models. Current Opinion in Nephrology and Hypertension, 2006, 15, 61-66.	1.0	25
234	Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrology Dialysis Transplantation, 2006, 22, 309-312.	0.4	60

#	ARTICLE	IF	CITATIONS
235	Kidneys, Hearts, Hormones and Immunomodulators: Integrated Understandings. Blood Purification, 2006, 24, 46-50.	0.9	7
236	Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrology Dialysis Transplantation, 2006, 21, 370-377.	0.4	65
237	Response to Letter Regarding Article by Khan et al, "Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease: A Meta-Analysis" Circulation, 2006, 113, .	1.6	1
238	Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2005, 67, 2089-2100.	2.6	2,836
239	Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?. Kidney International, 2005, 68, 1973-1981.	2.6	149
240	The need for optimal and coordinated management of CKD. Kidney International, 2005, 68, S7-S10.	2.6	30
241	Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKD. American Journal of Kidney Diseases, 2005, 46, 799-811.	2.1	179
242	A New Initiative in Nephrology: "Kidney Disease: Improving Global Outcomes"™. , 2005, 149, 90-99.		14
243	Multiple Risk Factor Intervention in Chronic Kidney Disease: Management of Cardiac Disease in Chronic Kidney Disease Patients. Medical Clinics of North America, 2005, 89, 511-523.	1.1	10
244	Effects of Early and Late Intervention with Epoetin A on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2004, 15, 148-156.	3.0	206
245	Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 1640-1647.	3.0	75
246	The burden of kidney disease: Improving global outcomes. Kidney International, 2004, 66, 1310-1314.	2.6	376
247	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiovascular Disease in Chronic Kidney Disease Prior to Dialysis. Seminars in Dialysis, 2003, 16, 101-105.	0.7	224
248	The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrology Dialysis Transplantation, 2003, 18, 1446-1451.	0.4	33
249	Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. Current Opinion in Nephrology and Hypertension, 2003, 12, 133-138.	1.0	17
250	National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Annals of Internal Medicine, 2003, 139, 137.	2.0	3,780
251	National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification, and Stratification. Pediatrics, 2003, 111, 1416-1421.	1.0	566
252	Nephrology: 4. Strategies for the care of adults with chronic kidney disease. Cmaj, 2003, 168, 1553-60.	0.9	7

#	ARTICLE	IF	CITATIONS
253	Association of Kidney Function With Anemia. Archives of Internal Medicine, 2002, 162, 1401.	4.3	613
254	The role of anaemia in the genesis of cardiac abnormalities in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2002, 17, 207-210.	0.4	13
255	Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrology Dialysis Transplantation, 2002, 17, 1426-1433.	0.4	37
256	Cardiovascular disease and the kidney. Postgraduate Medicine, 2002, 111, 53-60.	0.9	36
257	The relationship of haemoglobin level and survival: direct or indirect effects?. Nephrology Dialysis Transplantation, 2002, 17, 8-13.	0.4	24
258	Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney International, 2002, 61, S35-S38.	2.6	101
259	Should Hemoglobin be Normalized in Patients with Chronic Kidney Disease?. Seminars in Dialysis, 2002, 15, 8-13.	0.7	19
260	When does anemia impact the heart in chronic kidney disease?. , 2002, , 37-47.		0
261	Cardiovascular Disease in Patients with Chronic Kidney Disease: The Causes and Effects. , 2002, , 29-38.		0
262	Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. American Journal of Kidney Diseases, 2001, 37, 484-489.	2.1	184
263	Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. American Journal of Kidney Diseases, 2001, 38, 1398-1407.	2.1	193
264	Post-transplant diabetic ketoacidosis - A possible consequence of immunosuppression with calcineurin inhibiting agents: A case series. Transplant International, 2000, 13, 69-72.	0.8	16
265	Defining a renal anemia management period. American Journal of Kidney Diseases, 2000, 36, S13-S23.	2.1	43
266	Cardiovascular disease in chronic renal insufficiency. American Journal of Kidney Diseases, 2000, 36, S24-S30.	2.1	132
267	Post-transplant diabetic ketoacidosis - A possible consequence of immunosuppression with calcineurin inhibiting agents: A case series. Transplant International, 2000, 13, 69-72.	0.8	8
268	Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. American Journal of Kidney Diseases, 1999, 34, 125-134.	2.1	756
269	Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. American Journal of Kidney Diseases, 1996, 27, 347-354.	2.1	625